Soluble Guanylate Cyclase Stimulation on Cardiovascular Remodeling in Angiotensin II–Induced Hypertensive Rats-Reference-Cited by-同舟云学术

Soluble Guanylate Cyclase Stimulation on Cardiovascular Remodeling in Angiotensin II–Induced Hypertensive Rats

Published:2006-11 Issue:5 Volume:48 Page:972-978
ISSN:0194-911X
Container-title:Hypertension
language:en
Short-container-title:Hypertension

Author:

Masuyama Hiroyuki¹,Tsuruda Toshihiro¹,Kato Johji¹,Imamura Takuroh¹,Asada Yujiro¹,Stasch Johannes-Peter¹,Kitamura Kazuo¹,Eto Tanenao¹

Affiliation:

1. From the Department of Internal Medicine (H.M., T.T., J.K., T.I., K.K., T.E.), Circulatory and Body Fluid Regulation, and Department of Pathology (Y.A.), Faculty of Medicine, University of Miyazaki, Miyazaki, Japan; the Department of Nutrition Management (T.T.), Faculty of Health and Nutrition, Minami-Kyushu University, Miyazaki, Japan; and PharmD at Cardiovascular Research (J-P.S.), Bayer HealthCare, Wuppertal, Germany.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Internal Medicine

Reference27 articles.

1. Cardiac fibrosis and inflammation interaction with hemodynamic and hormonal factors

2. Relation of Left Ventricular Mass and Geometry to Morbidity and Mortality in Uncomplicated Essential Hypertension

3. Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart Study

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular Effects of Stimulators of Soluble Guanylate Cyclase Administration: A Meta-analysis of Randomized Controlled Trials;Current Atherosclerosis Reports;2024-04-02

2. Analysis of Mechanisms for Increased Blood Pressure Variability in Rats Continuously Infused with Angiotensin II;Journal of the Renin-Angiotensin-Aldosterone System;2023-01-04

3. Endothelial and vascular smooth muscle dysfunction in hypertension;Biochemical Pharmacology;2022-11

4. Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF);Biomedicine & Pharmacotherapy;2022-05

5. Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage;Current Hypertension Reports;2022-01